New Onco Immunotherapeutic approach for IL34 dependant cancer

L'innovation

IL-34 is as a cytokine promoting osteosarcoma progression by increasing the tissue vasculature, by stimulating the recruitment of macrophages and their differentiation toward M2 phenotype. Consequently, IL-34 appears as a pro-metastatic regulator in osteosarcoma.
IL34 produced by cancer cells is also involved in immunosuppression and chemoresistance.
We have developed an antibody binding IL34 with a high affinity. The IL34 antibody are capable of inhibiting IL34-mediated cell proliferation and intracellular signal transduction
By using a anti-IL34 antibody, we observed a total blockade of tumour progression in a syngenic model of osteosarcoma.

Ses bénéfices
Prevention of tumor growth and metastatic
Possible combination with conventional chemotherapy
No side effect

Ses applications
Osteosarcoma
Ewing sarcoma
Breast, prostate and lung cancer

Stade de développement
IN VIVO - Preuve de concept

Laboratoire de recherche
UMR_S 1238 - PHY-OS

Équipe de recherche
Sarcomes Osseux et Remodelage des Tissus Calcifiés

Propriété intellectuelle associée
EP : EP14199494 - filed on the 12-19-2014
WO - CA,EP,JP,US